Puma Biotechnology, Inc. (PBYI) has a MoatMap StockRank of 99/100 based on Quality (77/100), Value (63/100), and Momentum (64/100) factor scores. The current signal is STRONG BUY. Puma Biotechnology is a clinical-stage biotechnology company focused on oncology. While biotech companies can have intellectual property moats, they are characterized by high R&D intensity, significant binary risks associated with clinical trials and regulatory approvals, and often lack the stable, predictable cash flows and asset-light compounding nature preferred by Terry Smith and Buffett. There is no direct macro theme tailwind identified for this specific company, making it a product-specific bet rather than a macro-driven asymmetric opportunity.
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products for the treatment of cancer. Its lead product, Nerlynx, is approved for certain types of early-stage HER2-positive breast cancer. The company's competitive position is anchored by its approved oncology therapeutic and ongoing clinical development pipeline, operating in the high-stakes pharmaceutical market.
| Price | $7.08 |
| Market Cap | $360M |
| P/E (TTM) | 14.19 |
| P/E (Forward) | 19.46 |
| Price/Book | 2.63 |
| Return on Equity | 21.6% |
| Return on Invested Capital | 31.4% |
| Debt/Equity | 12.42 |
| Gross Margin | 74.5% |
| Operating Margin | -8.5% |
| Revenue Growth | -2.6% |
| Free Cash Flow | $44M |
Puma Biotechnology, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).